Details of the Drug

General Information of Drug (ID: DM7BN0X)

Drug Name

Esomeprazole

Synonyms

Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Approved	[1]
Gastrinoma	2C10.1	Approved	[1]
Laryngeal disorder	N.A.	Approved	[1]
Nausea	MD90	Approved	[1]
Peptic esophagitis	N.A.	Approved	[1]
Peptic ulcer	DA61	Approved	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiulcer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

345.4

Logarithm of the Partition Coefficient (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 3.85 mL/min/kg [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 1.5 hours [4]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.79 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.03% [4]
Vd: The volume of distribution (Vd) of drug is 16 L []
Water Solubility: The ability of drug to dissolve in water is measured as 0.5 mg/mL [3]

Chemical Identifiers

Formula: C17H19N3O3S
IUPAC Name: 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
Canonical SMILES: CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC
InChI: InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
InChIKey: SUBDBMMJDZJVOS-DEOSSOPVSA-N

Cross-matching ID

PubChem CID: 9568614
ChEBI ID: CHEBI:50275
CAS Number: 119141-88-7
DrugBank ID: DB00736
TTD ID: D0C6DT
INTEDE ID: DR0627
ACDINA ID: D00244

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase (Proton pump)	TTLOKXP	ATP4A_HUMAN ; ATP4B_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Esomeprazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Cefuroxime.	Acute bronchitis [CA42]	[9]
Glibenclamide	DM8JXPZ	Minor	Decreased metabolism of Esomeprazole caused by Glibenclamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[10]
Tolazamide	DMIHRNA	Minor	Decreased metabolism of Esomeprazole caused by Tolazamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[10]
Glipizide	DMZA5PQ	Minor	Decreased metabolism of Esomeprazole caused by Glipizide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[10]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Esomeprazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[11]
Framycetin	DMF8DNE	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Framycetin.	Alcoholic liver disease [DB94]	[12]
Paromomycin	DM1AGXN	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Paromomycin.	Amoebiasis [1A36]	[12]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Esomeprazole caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Posaconazole.	Aspergillosis [1F20]	[14]
Kanamycin	DM2DMPO	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Kanamycin.	Bacterial infection [1A00-1C4Z]	[12]
Clarithromycin	DM4M1SG	Minor	Decreased metabolism of Esomeprazole caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Streptomycin	DME1LQN	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Streptomycin.	Bacterial infection [1A00-1C4Z]	[12]
Cefpodoxime	DMJUNY5	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[9]
Gentamicin	DMKINJO	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Gentamicin.	Bacterial infection [1A00-1C4Z]	[12]
Bacampicillin	DMP54C7	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[9]
Netilmicin	DMRD1QK	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Netilmicin.	Bacterial infection [1A00-1C4Z]	[12]
Cefditoren	DMSUVM1	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[16]
Vismodegib	DM5IXKQ	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Vismodegib.	Basal cell carcinoma [2C32]	[15]
Pexidartinib	DMS2J0Z	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[17]
Lapatinib	DM3BH1Y	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Lapatinib.	Breast cancer [2C60-2C6Y]	[11]
HKI-272	DM6QOVN	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by HKI-272.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Bosutinib.	Breast cancer [2C60-2C6Y]	[18]
Atorvastatin	DMF28YC	Moderate	Decreased clearance of Esomeprazole and Atorvastatin due to competitive inhibition of the same transporter.	Cardiovascular disease [BA00-BE2Z]	[19]
Anisindione	DM2C48U	Moderate	Decreased metabolism of Esomeprazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[20]
Panitumumab	DMQPD1F	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Panitumumab.	Colorectal cancer [2B91]	[12]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Esomeprazole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[21]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Esomeprazole caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Esomeprazole caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[23]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Esomeprazole caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Esomeprazole caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Diazepam	DM08E9O	Moderate	Decreased metabolism of Esomeprazole caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Oxcarbazepine	DM5PU6O	Moderate	Decreased metabolism of Esomeprazole caused by Oxcarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Cenobamate	DM8KLU9	Moderate	Decreased metabolism of Esomeprazole caused by Cenobamate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Esomeprazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Phenobarbital	DMXZOCG	Minor	Decreased metabolism of Esomeprazole caused by Phenobarbital mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Ethacrynic acid.	Essential hypertension [BA00]	[27]
Itraconazole	DMCR1MV	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Itraconazole.	Fungal infection [1F29-1F2F]	[28]
Pentamidine	DMHZJCG	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Pentamidine.	Fungal infection [1F29-1F2F]	[12]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[28]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Chlorothiazide.	Heart failure [BD10-BD1Z]	[12]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Bumetanide.	Heart failure [BD10-BD1Z]	[12]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[12]
GS-5885	DMSL3DX	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by GS-5885.	Hepatitis virus infection [1E50-1E51]	[15]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Esomeprazole caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Fosamprenavir	DM4W9B3	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Fosamprenavir.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Tipranavir	DM8HJX6	Moderate	Increased metabolism of Esomeprazole caused by Tipranavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Esomeprazole caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Rilpivirine	DMJ0QOW	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Atazanavir	DMSYRBX	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Atazanavir.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Raltegravir	DMYURI6	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Esomeprazole caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[15]
Indapamide	DMGN1PW	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Indapamide.	Hypertension [BA00-BA04]	[12]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Trichlormethiazide.	Hypertension [BA00-BA04]	[12]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[12]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Esomeprazole caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[11]
Iron	DMAP8MV	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Iron.	Iron deficiency anaemia [3A00]	[34]
Ceritinib	DMB920Z	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Ceritinib.	Lung cancer [2C25]	[35]
Dacomitinib	DMOH8VY	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Dacomitinib.	Lung cancer [2C25]	[11]
Selpercatinib	DMZR15V	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Selpercatinib.	Lung cancer [2C25]	[11]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Esomeprazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
Acalabrutinib	DM7GCVW	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Acalabrutinib.	Mature B-cell lymphoma [2A85]	[37]
Ponatinib	DMYGJQO	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Ponatinib.	Mature B-cell lymphoma [2A85]	[15]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Esomeprazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[38]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Esomeprazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Nilotinib	DM7HXWT	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Nilotinib.	Myeloproliferative neoplasm [2A20]	[39]
Dasatinib	DMJV2EK	Major	Decreased absorption of Esomeprazole due to altered gastric pH caused by Dasatinib.	Myeloproliferative neoplasm [2A20]	[40]
Prasugrel	DM7MT6E	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[41]
Modafinil	DMYILBE	Moderate	Decreased metabolism of Esomeprazole caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[15]
Polythiazide	DMCH80F	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Polythiazide.	Oedema [MG29]	[12]
Carboplatin	DMG281S	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Carboplatin.	Ovarian cancer [2C73]	[12]
Aspirin	DM672AH	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Aspirin.	Pain [MG30-MG3Z]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Esomeprazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[43]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Esomeprazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[44]
Choline salicylate	DM8P137	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Choline salicylate.	Postoperative inflammation [1A00-CA43]	[42]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Esomeprazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[45]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Esomeprazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[46]
Riociguat	DMXBLMP	Moderate	Decreased absorption of Esomeprazole due to altered gastric pH caused by Riociguat.	Pulmonary hypertension [BB01]	[47]
Axitinib	DMGVH6N	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Axitinib.	Renal cell carcinoma [2C90]	[48]
Salsalate	DM13P4C	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Salsalate.	Rheumatoid arthritis [FA20]	[42]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Esomeprazole caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Salicyclic acid	DM2F8XZ	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[42]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Esomeprazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Esomeprazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Vandetanib	DMRICNP	Minor	Decreased absorption of Esomeprazole due to altered gastric pH caused by Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Esomeprazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[49]
Clopidogrel	DMOL54H	Major	Decreased metabolism of Esomeprazole caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[50]
Tolbutamide	DM02AWV	Minor	Decreased metabolism of Esomeprazole caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[10]
Plazomicin	DMKMBES	Moderate	Increased risk of hypomagnesemia by the combination of Esomeprazole and Plazomicin.	Urinary tract infection [GC08]	[12]
-----------


⏷ Show the Full List of 88 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
Carminic acid	E00506	10255083	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydroxyethylamine	E00022	700	Alkalizing agent; Emulsifying agent; Solvent
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Meglumine	E00181	8567	Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate	E00453	2724691	Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium hydrogenphosphate	E00294	24441	Diluent
Dextrose anhydrous	E00394	107526	Binding agent; Diluent; Flavoring agent; Tonicity agent
Diglycerin	E00343	42953	Humectant; Solubilizing agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate	E00205	11029	Adsorbent; Diluent
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 45 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Esomeprazole 20 mg capsule	20 mg	Delayed Release Oral Capsule	Oral
Esomeprazole 40 mg capsule	40 mg	Delayed Release Oral Capsule	Oral
Esomeprazole 49.3 mg capsule	49.3 mg	Delayed Release Oral Capsule	Oral
Esomeprazole 20 mg tablet	20 mg	Delayed Release Oral Tablet	Oral
Esomeprazole 24.65 mg capsule	24.65 mg	Delayed Release Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Esomeprazole FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488).
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
8	The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol In Vitro. 2015 Aug;29(5):1088-99.
9	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
10	Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
13	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
14	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
15	Cerner Multum, Inc. "Australian Product Information.".
16	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
17	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
19	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
20	Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
21	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
22	Cerner Multum, Inc. "Canadian Product Information.".
23	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
24	Canadian Pharmacists Association.
25	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
26	Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
27	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
28	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
29	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
30	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
31	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
32	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
33	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
34	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
35	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
37	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
38	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
39	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
41	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
42	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
43	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
45	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
46	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
47	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
48	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
50	Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]